The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Open accessAbstract
Summary Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy. We discovered 3 molecular subtypes of MIBC that resembled established molecular subtypes of breast cancer. Basal MIBCs shared biomarkers with basal breast cancers and were characterized by p63 activation, squamous differentiation, and more aggressive disease at presentation. Luminal MIBCs contained features of active PPARγ and estrogen receptor (ER) transcription and were enriched with activating FGFR3 mutations and potentially FGFR inhibitor sensitivity. p53-like MIBCs were consistently resistant to neoadjuvant MVAC chemotherapy, and all chemoresistant tumors adopted a p53-like phenotype after therapy. Our observations have important implications for prognostication, the future clinical development of targeted agents, and disease management with conventional chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121 · cited 1×
“Although they expressed epithelial cytokeratins, basal tumors also contained ‘‘mesenchymal’’ biomarkers (i.e., TWIST1/2, SNAI2, ZEB2, and VIM;McConkey et al., 2010; Peinado et al., 2007; Figure S1B), as do basal breast cancers (Chaffer et al., 2013).”
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022148 · Cited by 2,668
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
A Molecular Taxonomy for Urothelial Carcinoma
Sjödahl, G., Lauss, M., Lövgren, K., Chebil, G., Gudjonsson, S., Veerla, S., Patschan, O., Aine, M., Fernö, M., Ringnér, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0077-t · Cited by 944
Chaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 876
The health economics of bladder cancer: A comprehensive review of the published literature
Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., & Hauser, R. (2003) · PharmacoEconomics · doi:10.1007/bf03262330 · Cited by 860
Hatakeyama, S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3139 · Cited by 802
Chan, K. S., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., Gill, H., Presti, J., Chang, H. Y., van de Rijn, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906549106 · Cited by 660
Sanchez-Carbayo, M., Socci, N. D., Lozano, J., Saint, F., & Cordon-Cardo, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2375 · Cited by 550
Identifying distinct classes of bladder carcinoma using microarrays
Dyrskjøt, L., Thykjaer, T., Kruhøffer, M., Jensen, J. L., Marcussen, N., Hamilton-Dutoit, S., Wolf, H., & Ørntoft, T. F. (2003) · Nature Genetics · doi:10.1038/ng1061 · Cited by 501
Esserman, L. J., Berry, D. A., DeMichele, A., Carey, L., Davis, S. E., Buxton, M., Hudis, C., Gray, J. W., Perou, C., Yau, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2779 · Cited by 438
TRIM24 links a non-canonical histone signature to breast cancer
Tsai, W.-W., Wang, Z., Yiu, T. T., Akdemir, K. C., Xia, W., Winter, S., Tsai, C.-Y., Shi, X., Schwarzer, D., Plunkett, W., et al. (2010) · Nature · doi:10.1038/nature09542 · Cited by 434
Kim, W.-J., Kim, E.-J., Kim, S.-K., Kim, Y.-J., Ha, Y.-S., Jeong, P., Kim, M.-J., Yun, S.-J., Lee, K., Moon, S.-K., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-3 · Cited by 398
Self-citationThe I-SPY 1 TRIAL Investigators, Esserman, L. J., Berry, D. A., Cheang, M. C. U., Yau, C., Perou, C. M., Carey, L., DeMichele, A., Gray, J. W., Conway-Dorsey, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1895-2 · Cited by 362
Lee, J.-S., Leem, S.-H., Lee, S.-Y., Kim, S.-C., Park, E.-S., Kim, S.-B., Kim, S.-K., Kim, Y.-J., Kim, W.-J., & Chu, I.-S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0977 · Cited by 342
Self-citationBladder Cancer Outcome and Subtype Classification by Gene Expression
Blaveri, E., Simko, J. P., Korkola, J. E., Brewer, J. L., Baehner, F., Mehta, K., DeVries, S., Koppie, T., Pejavar, S., Carroll, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2409 · Cited by 337
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
Lee, J. K., Havaleshko, D. M., Cho, H., Weinstein, J. N., Kaldjian, E. P., Karpovich, J., Grimshaw, A., & Theodorescu, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610292104 · Cited by 316
Dinney, C. P. N., McConkey, D. J., Millikan, R. E., Wu, X., Bar-Eli, M., Adam, L., Kamat, A. M., Siefker-Radtke, A. O., Tuziak, T., Sabichi, A. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.002 · Cited by 290
Self-citationMillikan, R., Dinney, C., Swanson, D., Sweeney, P., Ro, J. Y., Smith, T. L., Williams, D., & Logothetis, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4005 · Cited by 271
Self-citationMolecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression
McConkey, D. J., Lee, S., Choi, W., Tran, M., Majewski, T., Lee, S., Siefker-Radtke, A., Dinney, C., & Czerniak, B. (2010) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.04.008 · Cited by 228
Self-citationShen, S. S., Smith, C. L., Hsieh, J., Yu, J., Kim, I. Y., Jian, W., Sonpavde, G., Ayala, G. E., Younes, M., & Lerner, S. P. (2006) · Cancer · doi:10.1002/cncr.21945 · Cited by 192
Normal and neoplastic urothelial stem cells: getting to the root of the problem
Ho, P. L., Kurtova, A., & Chan, K. S. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.142 · Cited by 184
Romano, R.-A., Ortt, K., Birkaya, B., Smalley, K., & Sinha, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005623 · Cited by 165
Workman, P. (1995) · Human & Experimental Toxicology · doi:10.1177/096032719501400213 · Cited by 165
Continuous Nucleocytoplasmic Shuttling Underlies Transcriptional Activation of PPARγ by FABP4
Ayers, S. D., Nedrow, K. L., Gillilan, R. E., & Noy, N. (2007) · Biochemistry · doi:10.1021/bi700047a · Cited by 163
Bladder Squamous Cell Carcinomas Express Psoriasin and Externalize it to the Urine
Celis, J. E., Rasmussen, H. H., Vorum, H., Madsen, P., Honoré, B., Wolf, H., & Orntoft, T. F. (1996) · The Journal of Urology · doi:10.1016/s0022-5347(01)66118-4 · Cited by 147
Karni-Schmidt, O., Castillo-Martín, M., HuaiShen, T., Gladoun, N., Domenech, J. M. D., Sänchez‐Carbayo, M., Li, Y., Lowe, S. W., Prives, C. L., & Cordon‐Cardo, C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.061 · Cited by 145
New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine
Shah, J. B., McConkey, D. J., & Dinney, C. P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2770 · Cited by 108
Self-citationp63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers
Choi, W., Shah, J. B., Tran, M., Svatek, R. S., Marquis, L., Lee, I.-L., Yu, D., Adam, L., Wen, S., Shen, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030206 · Cited by 104
Self-citationBoldrup, L., Coates, P. J., Gu, X., & Nylander, K. (2007) · The Journal of Pathology · doi:10.1002/path.2237 · Cited by 62
p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells
Marquis, L., Tran, M., Choi, W., Lee, I.-L., Huszar, D., Siefker-Radtke, A. O., Dinney, C. P., & McConkey, D. J. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19590 · Cited by 23
Self-citation
Cited by
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
Self-citationBalar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Self-citationUpdated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
Alfred Witjes, J., Lebret, T., Compérat, E. M., Cowan, N. C., De Santis, M., Bruins, H. M., Hernández, V., Espinós, E. L., Dunn, J., Rouanne, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.020 · Cited by 1,476
Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., & Kassouf, W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30512-8 · Cited by 1,421
Self-citationA Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Kamoun, A., de Reyniès, A., Allory, Y., Sjödahl, G., Robertson, A. G., Seiler, R., Hoadley, K. A., Groeneveld, C. S., Al-Ahmadie, H., Choi, W., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.09.006 · Cited by 1,359
Self-citation
Metadata
- Authors
- Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., Melquist, J., Bondaruk, J., Majewski, T., Zhang, S., Pretzsch, S., Baggerly, K., Siefker-Radtke, A., Czerniak, B., Dinney, C. P. N., & McConkey, D. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 25
- Issue
- 2
- Pages
- 152-165
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2033775272
- Cited by
- 1,716
- References
- 40
- FWCI
- 120.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.